We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+26.31%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$471M
AUM Growth
-$10.2M
Cap. Flow
-$72.7M
Cap. Flow %
-15.44%
Top 10 Hldgs %
41.74%
Holding
94
New
28
Increased
11
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$9.06M
2
XLRN
Acceleron Pharma
XLRN
+$9.03M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.53M
4
IMMU
Immunomedics Inc
IMMU
+$7.44M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$7.03M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$15.5M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.2M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.95M
4
ENDP
Endo International plc
ENDP
+$8.38M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.03M

Sector Composition

Rank Sector Weight
1 Healthcare 57.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
51
Rigel Pharmaceuticals
RIGL
$750M
$2.79M 0.59%
110,000
– –
BCRX icon
52
BioCryst Pharmaceuticals
BCRX
$2.36B
$2.62M 0.56%
500,000
-175,000
-26% -$896K
ICPT
53
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.03M 0.43%
+35,000
New +$3.77M
PTCT icon
54
CALL
PTC Therapeutics
PTCT
$6.52B
$2M 0.42%
+100,000
New +$1.96M
PTCT icon
55
PTC Therapeutics
PTCT
$6.52B
$2M 0.42%
100,000
-100,000
-50% -$1.96M
IRIX icon
56
IRIDEX
IRIX
$16.3M
$1.87M 0.4%
199,519
-50,481
-20% -$459K
NUVA
57
DELISTED
NuVasive, Inc.
NUVA
$1.66M 0.35%
30,000
-70,000
-70% -$4.63M
EXEL icon
58
Exelixis
EXEL
$14.1B
$1.3M 0.28%
+53,500
New +$1.42M
DCPH
59
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.22M 0.26%
+64,410
New +$1.18M
NBRV
60
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$983K 0.21%
+480
New +$1.13M
QTNT
61
DELISTED
Quotient Limited Ordinary Shares
QTNT
$924K 0.2%
4,686
-2,814
-38% -$562K
SIOX
62
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$688K 0.15%
12,500
-9,375
-43% -$1.58M
ARAV
63
DELISTED
Aravive, Inc. Common Stock
ARAV
$674K 0.14%
+45,833
New +$4.62M
ACAD icon
64
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-275,000
Closed -$8.95M
ATRA icon
65
Atara Biotherapeutics
ATRA
$75.6M
– –
-14,000
Closed -$4.9M
BPMC
66
DELISTED
Blueprint Medicines
BPMC
– –
-70,000
Closed -$3.55M
ENTA icon
67
Enanta Pharmaceuticals
ENTA
$400M
– –
-200,000
Closed -$7.2M
EXEL icon
68
PUT
Exelixis
EXEL
$14.1B
– –
-300,000
Closed -$7.39M
GILD icon
69
Gilead Sciences
GILD
$167B
– –
-75,000
Closed -$5.31M
IOVA icon
70
Iovance Biotherapeutics
IOVA
$2.23B
– –
-550,000
Closed -$4.04M
MRK icon
71
CALL
Merck
MRK
$315B
– –
-209,600
Closed -$12.8M
SAGE
72
DELISTED
Sage Therapeutics
SAGE
– –
-50,000
Closed -$3.93M
SNDX icon
73
Syndax Pharmaceuticals
SNDX
$2.02B
– –
-200,000
Closed -$2.79M
ITCI
74
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-500,000
Closed -$6.21M
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-200,000
Closed -$2.48M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Ghost Tree Capital held 94 positions worth $471M, down 2.1% from $481M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $72.7M in Q3 2017, closing 31 positions and reducing 21 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 59% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Thermo Fisher Scientific worth $9.46M.

  • Ghost Tree Capital's largest Q3 2017 buy was Thermo Fisher Scientific: 50,000 shares worth $9.46M.
  • Ghost Tree Capital added most to Acceleron Pharma in Q3 2017, an estimated $9.03M increase.
  • Ghost Tree Capital's biggest Q3 2017 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.03M.
  • Ghost Tree Capital fully exited Seagen Inc. Common Stock in Q3 2017, selling an estimated $15.5M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $471M portfolio in Q3 2017.
  • Ghost Tree Capital opened 28 new positions and closed 31 in Q3 2017.
  • Ghost Tree Capital's portfolio value fell 2.1% quarter-over-quarter to $471M.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.